Related resources and publications
Humanized ICP mouse and cell lines
Humanized PD-1/PD-L1 mouse and cell line
Humanized PD-1 & GITR mouse
T-cell engager
Assess toxicity with ICP
Immuno-oncolology models
The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.
The humanized CD28 model, developed by Knockin at the mouse CD28 locus, expresses a chimeric CD28 with a human extracellular and murine transmembrane and intracellular domains. The design also gives access to CD28 conditional Knockout mice.
hCD28 and mCD28 expression on freshly isolated splenocytes on (A) CD8+ (viable, CD3+CD8+) T cells, (B) conventional CD4+ (viable, CD3+CD4+Foxp3-), and (C) Tregs (viable, CD3+CD4+CD25+Foxp3+).
Isolated T cells were labeled with CTV and activated with αCD3 and soluble mouse or human αCD28 for 4 days. Representative FACS bar graphs indicating (A) CD25 expression as a marker of activation, and (B) CTV dilution (as a measure of proliferation) gated on live T cells. Results are expressed as mean±SD. Unpaired T test analyses (**p<0.01, ***p<0.001).
Humanized ICP mouse and cell lines
Humanized PD-1/PD-L1 mouse and cell line
Humanized PD-1 & GITR mouse
T-cell engager
Assess toxicity with ICP
Immuno-oncolology models
The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.
Let us know how we can help